Cargando…

The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection

Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simi...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles, Tysheena P., Burton, Samantha L., Arunachalam, Prabhu S., Cottrell, Christopher A., Sewall, Leigh M., Bollimpelli, Venkata S., Gangadhara, Sailaja, Dey, Antu K., Ward, Andrew B., Shaw, George M., Hunter, Eric, Amara, Rama R., Pulendran, Bali, van Gils, Marit J., Derdeyn, Cynthia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895394/
https://www.ncbi.nlm.nih.gov/pubmed/33556148
http://dx.doi.org/10.1371/journal.ppat.1009257
_version_ 1783653355851087872
author Charles, Tysheena P.
Burton, Samantha L.
Arunachalam, Prabhu S.
Cottrell, Christopher A.
Sewall, Leigh M.
Bollimpelli, Venkata S.
Gangadhara, Sailaja
Dey, Antu K.
Ward, Andrew B.
Shaw, George M.
Hunter, Eric
Amara, Rama R.
Pulendran, Bali
van Gils, Marit J.
Derdeyn, Cynthia A.
author_facet Charles, Tysheena P.
Burton, Samantha L.
Arunachalam, Prabhu S.
Cottrell, Christopher A.
Sewall, Leigh M.
Bollimpelli, Venkata S.
Gangadhara, Sailaja
Dey, Antu K.
Ward, Andrew B.
Shaw, George M.
Hunter, Eric
Amara, Rama R.
Pulendran, Bali
van Gils, Marit J.
Derdeyn, Cynthia A.
author_sort Charles, Tysheena P.
collection PubMed
description Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simian-human immunodeficiency virus (SHIV) challenge that was predicted by high serum nAb titers. Here, we show that nAb in these protected RM targeted a glycan hole proximal to residue 465 in gp120 in all cases. nAb also targeted another glycan hole at residues 241/289 and an epitope in V1 at varying frequencies. Non-neutralizing antibodies directed at N611-shielded epitopes in gp41 were also present but were more prevalent in RM with low nAb titers. Longitudinal analysis demonstrated that nAb broadened in some RM during sequential immunization but remained focused in others, the latter being associated with increases in nAb titer. Thirty-eight monoclonal antibodies (mAbs) isolated from a protected RM with an exceptionally high serum neutralization titer bound to the trimer in ELISA, and four of the mAbs potently neutralized the BG505 Env pseudovirus (PV) and SHIV. The four neutralizing mAbs were clonally related and targeted the 465 glycan hole to varying degrees, mimicking the serum. The data demonstrate that the C3/465 glycan hole cluster was the dominant neutralization target in high titer protected RM, despite other co-circulating neutralizing and non-neutralizing specificities. The isolation of a neutralizing mAb family argues that clonotype expansion occurred during BG505 SOSIP immunization, leading to high titer, protective nAb and setting a desirable benchmark for HIV vaccines.
format Online
Article
Text
id pubmed-7895394
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-78953942021-03-01 The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection Charles, Tysheena P. Burton, Samantha L. Arunachalam, Prabhu S. Cottrell, Christopher A. Sewall, Leigh M. Bollimpelli, Venkata S. Gangadhara, Sailaja Dey, Antu K. Ward, Andrew B. Shaw, George M. Hunter, Eric Amara, Rama R. Pulendran, Bali van Gils, Marit J. Derdeyn, Cynthia A. PLoS Pathog Research Article Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simian-human immunodeficiency virus (SHIV) challenge that was predicted by high serum nAb titers. Here, we show that nAb in these protected RM targeted a glycan hole proximal to residue 465 in gp120 in all cases. nAb also targeted another glycan hole at residues 241/289 and an epitope in V1 at varying frequencies. Non-neutralizing antibodies directed at N611-shielded epitopes in gp41 were also present but were more prevalent in RM with low nAb titers. Longitudinal analysis demonstrated that nAb broadened in some RM during sequential immunization but remained focused in others, the latter being associated with increases in nAb titer. Thirty-eight monoclonal antibodies (mAbs) isolated from a protected RM with an exceptionally high serum neutralization titer bound to the trimer in ELISA, and four of the mAbs potently neutralized the BG505 Env pseudovirus (PV) and SHIV. The four neutralizing mAbs were clonally related and targeted the 465 glycan hole to varying degrees, mimicking the serum. The data demonstrate that the C3/465 glycan hole cluster was the dominant neutralization target in high titer protected RM, despite other co-circulating neutralizing and non-neutralizing specificities. The isolation of a neutralizing mAb family argues that clonotype expansion occurred during BG505 SOSIP immunization, leading to high titer, protective nAb and setting a desirable benchmark for HIV vaccines. Public Library of Science 2021-02-08 /pmc/articles/PMC7895394/ /pubmed/33556148 http://dx.doi.org/10.1371/journal.ppat.1009257 Text en © 2021 Charles et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Charles, Tysheena P.
Burton, Samantha L.
Arunachalam, Prabhu S.
Cottrell, Christopher A.
Sewall, Leigh M.
Bollimpelli, Venkata S.
Gangadhara, Sailaja
Dey, Antu K.
Ward, Andrew B.
Shaw, George M.
Hunter, Eric
Amara, Rama R.
Pulendran, Bali
van Gils, Marit J.
Derdeyn, Cynthia A.
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title_full The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title_fullStr The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title_full_unstemmed The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title_short The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
title_sort c3/465 glycan hole cluster in bg505 hiv-1 envelope is the major neutralizing target involved in preventing mucosal shiv infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895394/
https://www.ncbi.nlm.nih.gov/pubmed/33556148
http://dx.doi.org/10.1371/journal.ppat.1009257
work_keys_str_mv AT charlestysheenap thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT burtonsamanthal thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT arunachalamprabhus thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT cottrellchristophera thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT sewallleighm thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT bollimpellivenkatas thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT gangadharasailaja thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT deyantuk thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT wardandrewb thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT shawgeorgem thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT huntereric thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT amararamar thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT pulendranbali thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT vangilsmaritj thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT derdeyncynthiaa thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT charlestysheenap c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT burtonsamanthal c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT arunachalamprabhus c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT cottrellchristophera c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT sewallleighm c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT bollimpellivenkatas c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT gangadharasailaja c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT deyantuk c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT wardandrewb c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT shawgeorgem c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT huntereric c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT amararamar c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT pulendranbali c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT vangilsmaritj c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection
AT derdeyncynthiaa c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection